# Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

> **NCT05962840** · PHASE4 · RECRUITING · sponsor: **Chinese SLE Treatment And Research Group** · enrollment: 40 (estimated)

## Conditions studied

- ANCA Associated Vasculitis

## Interventions

- **DRUG:** Telitacicept
- **OTHER:** Placebo of Telitacicept

## Key facts

- **NCT ID:** NCT05962840
- **Lead sponsor:** Chinese SLE Treatment And Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-29
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05962840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05962840, "Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05962840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*